Intuitive Surgical (ISRG) Just Beat Earnings. Is the Stock Still Worth Paying a Premium?

Intuitive Surgical (ISRG) beat Q2 2026 earnings and revenue estimates, but its stock dropped due to investor concerns about slowing domestic procedure growth. Despite this, UBS upgraded the stock, citing potential for dramatic acceleration in procedure penetration, strong profitability margins, and robust recurring revenue streams. The article explores both the bullish and bearish cases for ISRG, highlighting factors like competitive landscape, tariff impacts, and the importance of monitoring procedure growth and adoption of new technologies.